| A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. | |
| | |
MedLine Citation:
|
PMID: 20739907 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We reported earlier on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on seven single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3' end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype. The agreement between the 7-SNP NAT2 inferred phenotype and the tag SNP, rs1495741, was initially assessed in 2174 individuals from the Spanish Bladder Cancer Study (SBCS), and confirmed in a subset of individuals from the Main and Vermont component the New England Bladder Cancer Study (NEBCS). We also investigated the association of rs1495741 genotypes with NAT2 catalytic activity in cryopreserved hepatocytes from 154 individuals of European background. We observed very strong agreement between rs1495741 and the 7-SNP inferred NAT2 phenotype: sensitivity and specificity for the NAT2 slow phenotype was 99 and 95%, respectively. Our findings were replicated in an independent population from the NEBCS. Estimates for the association between NAT2 slow phenotype and bladder cancer risk in the SBCS and its interaction with cigarette smoking were comparable for the 7-SNP inferred NAT2 phenotype and rs1495741. In addition, rs1495741 genotypes were strongly related to NAT2 activity measured in hepatocytes (P<0.0001). A novel NAT2 tag SNP (rs1495741) predicts with high accuracy the 7-SNP inferred NAT2 phenotype, and thus can be used as a sole marker in pharmacogenetic or epidemiological studies of populations of European background. These findings illustrate the utility of tag SNPs, often used in genome-wide association studies (GWAS), to identify novel phenotypic markers. Further studies are required to determine the functional implications of rs1495741 and the structure and evolution of the haplotype on which it resides. |
| | |
Authors:
|
Montserrat García-Closas; David W Hein; Debra Silverman; Núria Malats; Meredith Yeager; Kevin Jacobs; Mark A Doll; Jonine D Figueroa; Dalsu Baris; Molly Schwenn; Manolis Kogevinas; Alison Johnson; Nilanjan Chatterjee; Lee E Moore; Timothy Moeller; Francisco X Real; Stephen Chanock; Nathaniel Rothman |
Related Documents
:
|
20038957 - A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resist... 20951227 - Exposure to low environmental levels of benzene: evaluation of micronucleus frequencies... 19181737 - Rapid single-nucleotide polymorphism detection of cytochrome p450 (cyp2c9) and vitamin ... 10465337 - A multiplex-pcr/rflp procedure for simultaneous cyp2e1, meh and gstm1 genotyping. 17275867 - Long-term evolution of polygenic traits under frequency-dependent intraspecific competi... 8880537 - Genotyping of hepatitis c virus isolates from lebanese hemodialysis patients by reverse... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pharmacogenetics and genomics Volume: 21 ISSN: 1744-6880 ISO Abbreviation: Pharmacogenet. Genomics Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-16 Completed Date: 2011-07-22 Revised Date: 2012-04-04 |
Medline Journal Info:
|
Nlm Unique ID: 101231005 Medline TA: Pharmacogenet Genomics Country: United States |
Other Details:
|
Languages: eng Pagination: 231-6 Citation Subset: IM |
Affiliation:
|
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD, USA. Montse.GarciaClosas@icr.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Arylamine N-Acetyltransferase
/
genetics* Case-Control Studies European Continental Ancestry Group / genetics Genotype Haplotypes Humans New England Phenotype* Polymorphism, Single Nucleotide / genetics* Spain Vermont |
| Grant Support | |
ID/Acronym/Agency:
|
N02-CP-01037/CP/NCI NIH HHS; N02-CP-11015/CP/NCI NIH HHS; R01-CA034627/CA/NCI NIH HHS; Z99 CA999999/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
EC 2.3.1.5/Arylamine N-Acetyltransferase; EC 2.3.1.5/NAT2 protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
Next Document: PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.